Measles immunisation – European Clinical Trials Information Network

Evaluating measles, mumps, rubella vaccine (live) in lactating women to enhance infant mucosal immunity

Wed, 29 Apr 2026 15:09:57 +0000

The study examines protection against Measles (as well as the related mumps and rubella viruses) by giving a booster dose of the live vaccine M-M-RvaxPro to mothers while they are nursing. The vaccine contains weakened viruses that trigger the body’s defense system without causing illness, and it is given as an injection into the muscle.

The purpose is to find out whether a booster given during lactation increases the amount of protective antibodies in breastmilk over three months compared with mothers who do not receive the vaccine. Mothers receive a single injection and then provide breastmilk samples about five times during the three‑month period. Antibodies are proteins that recognize and help neutralize germs, and the humoral immune response refers to this antibody‑based protection. The study also checks the activity of immune cells in the milk.

Study on Early Measles Immunization with MMR-0 Vaccine for Infants Under 12 Months During a Measles Outbreak

Wed, 29 Apr 2026 15:05:49 +0000

This clinical trial is focused on studying the effects of early vaccination against measles during an outbreak. The study involves healthy infants who will receive a vaccine called M-M-RvaxPro, which is designed to protect against measles, mumps, and rubella. This vaccine contains live, weakened forms of the viruses that cause these diseases. Another vaccine, Nimenrix, which protects against certain types of meningococcal infections, is also part of the study.

The purpose of the study is to assess how well infants’ immune systems respond to the early administration of the measles vaccine, known as MMR-0, when given to children younger than 12 months during a measles outbreak. The study will compare the immune response of infants who receive the MMR-0 vaccine with those who receive the standard measles vaccine, MMR-1, at 14 months of age. The study will monitor the levels of antibodies, which are proteins the body makes to fight infections, in the infants’ blood at different times after vaccination.

Participants in the study will receive the vaccines through an injection into the muscle. The study will track the infants’ immune responses over time, including four weeks after the MMR-0 vaccination and up to one year after the MMR-1 vaccination. The study aims to provide valuable information on the effectiveness and safety of early measles vaccination in young children during an outbreak.

Study on Immune Response and Safety of Measles, Mumps, Rubella, and Varicella Vaccine in Healthy Children Aged 4 to 6 Years

Wed, 29 Apr 2026 15:05:18 +0000

This clinical trial is focused on studying the immune response and safety of a new vaccine for preventing infections caused by the measles, mumps, rubella, and varicella (chickenpox) viruses. The study involves healthy children aged 4 to 6 years. The new vaccine is being compared to an existing vaccine called ProQuad, which is already available on the market. The new vaccine contains live, weakened strains of the viruses that cause these diseases, similar to the ProQuad vaccine.

The purpose of the study is to evaluate how well the new vaccine works in generating an immune response, which is the body’s way of defending against infections. The study will also assess the safety of the vaccine by monitoring any side effects that may occur. Children participating in the study will receive either the new vaccine or the ProQuad vaccine. The vaccines are given as a single injection under the skin, and the study will follow the children for several months to observe their immune response and any side effects.

Throughout the study, researchers will measure the levels of antibodies, which are proteins made by the immune system to fight infections, in the children’s blood. These measurements will help determine how effectively the vaccines protect against the viruses. The study will also track any common side effects, such as fever or rash, and any serious adverse events that might occur. The goal is to ensure that the new vaccine is both effective and safe for use in children.